Home Products PF 04691502
PF 04691502
Synonyms:
CAS NO: 1013101-36-4
Molecular Formula: C22H27N5O4
Molecular Weight: 425.48
Purity: 98% min
Solubility: In DMSO
Storage: -20°C
Availability and Price
20MG/$300 In-stock If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
50MG/$500 In-stock
100MG/$800 In-stock Order       Order Infomation
200MG/$1500 In-stock
Shipping and handling fee USD40
Free delivery is qualified when the total value of your order exceeds 500USD
Remarks: PF-04691502 is a potent and selective dual PI3K/mTOR inhibitor to phosphorylation of AKT T308 and AKT S473 with IC50 of 7.5 and 3.8 nM, respectively. PF-04691502 is an ATP-competitive inhibitor which potently inhibits recombinant class I PI3K and mTOR in biochemical assays and suppresses transformation of avian fibroblasts mediated by wild type PI3K, or mutant PI3K.PF-04691502 has potential antineoplastic activity. In PIK3CA-mutant and PTEN-deleted cancer cell lines, PF-04691502 decreases phosphorylation of AKT T308 and AKT S473 with IC50 ranging from 7.5 to 47 nM and from 3.8 to 20 nM respectively, and inhibits cell proliferation with IC50 ranging from 179 to 313 nM. In addition, PF-04691502 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. PF-04691502 inhibits mTORC1 activity in cells as measured by PI3K-independent nutrient stimulated assay, with an IC50 of 32 nM and inhibits the activation of PI3K and mTOR downstream effectors including AKT, FKHRL1, PRAS40, p70S6K, 4EBP1 and S6RP. Short-term exposure to PF-04691502 predominantly inhibits PI3K, while mTOR inhibition persists for 24-48 hours. PF-04691502 causes cell cycle G1 arrest, concomitant with upregulation of p27 Kip1 and reduction of Rb. Antitumor activity is observed in U87 (PTEN null), SKOV3 (PIK3CA mutation) and gefitinib- and erlotinib-resistant NSCLC xenografts. PF-04691502 is originally developed by Pfizer. PF-04691502 is under a phase II clinical trial in the treatment of endometrial neoplasms

Quality Control

Quality Control by H-NMR,C-NMR,LC-MS,HPLC.
Related Products
AKT Inhibitors
 

None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer.

Our products are for research use only, not for human use.
 
Homepage | About Us | Products | News&Events | Custom Synthesis | Order Infomation | Contact Us
Friendly link: molbase   Copyright © Taizhou Crene Biotechnology Co.,Ltd. 技术支持:趋势科技